Compare SEDG & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEDG | INVA |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2015 | 2000 |
| Metric | SEDG | INVA |
|---|---|---|
| Price | $33.46 | $20.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 25 | 5 |
| Target Price | ★ $37.84 | $35.00 |
| AVG Volume (30 Days) | ★ 2.2M | 619.0K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 78.26 | ★ 816.67 |
| EPS | N/A | ★ 1.25 |
| Revenue | ★ $1,184,444,000.00 | $217,217,000.00 |
| Revenue This Year | $9.81 | $9.72 |
| Revenue Next Year | $10.13 | $8.58 |
| P/E Ratio | ★ N/A | $16.86 |
| Revenue Growth | 31.39 | ★ 62.63 |
| 52 Week Low | $28.21 | $17.45 |
| 52 Week High | $81.25 | $25.15 |
| Indicator | SEDG | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 45.08 |
| Support Level | $32.49 | $20.40 |
| Resistance Level | $35.08 | $21.69 |
| Average True Range (ATR) | 1.74 | 0.47 |
| MACD | 0.26 | -0.01 |
| Stochastic Oscillator | 67.21 | 9.60 |
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.